Pharmacogenetics of Oral Antidiabetic Drugs
Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations d...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2013/686315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548769463271424 |
|---|---|
| author | Matthijs L. Becker Ewan R. Pearson Ivan Tkáč |
| author_facet | Matthijs L. Becker Ewan R. Pearson Ivan Tkáč |
| author_sort | Matthijs L. Becker |
| collection | DOAJ |
| description | Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. SLC22A1 and SLC47A1 encode metformin transporters OCT1 and MATE1, respectively. The function of a gene variant near ATM gene identified by a genome-wide association study is not elucidated so far. The first variant associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen. Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future. |
| format | Article |
| id | doaj-art-78400745444641b3a1c5e876f9fe2924 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-78400745444641b3a1c5e876f9fe29242025-02-03T06:13:06ZengWileyInternational Journal of Endocrinology1687-83371687-83452013-01-01201310.1155/2013/686315686315Pharmacogenetics of Oral Antidiabetic DrugsMatthijs L. Becker0Ewan R. Pearson1Ivan Tkáč2Department of Epidemiology, Erasmus MC, 3015 CE Rotterdam, The NetherlandsMedical Research Institute, University of Dundee, Dundee DD1 9SY, UKDepartment of Internal Medicine 4, Faculty of Medicine, P. J. Šafárik University, 041 80 Košice, SlovakiaOral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. SLC22A1 and SLC47A1 encode metformin transporters OCT1 and MATE1, respectively. The function of a gene variant near ATM gene identified by a genome-wide association study is not elucidated so far. The first variant associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen. Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future.http://dx.doi.org/10.1155/2013/686315 |
| spellingShingle | Matthijs L. Becker Ewan R. Pearson Ivan Tkáč Pharmacogenetics of Oral Antidiabetic Drugs International Journal of Endocrinology |
| title | Pharmacogenetics of Oral Antidiabetic Drugs |
| title_full | Pharmacogenetics of Oral Antidiabetic Drugs |
| title_fullStr | Pharmacogenetics of Oral Antidiabetic Drugs |
| title_full_unstemmed | Pharmacogenetics of Oral Antidiabetic Drugs |
| title_short | Pharmacogenetics of Oral Antidiabetic Drugs |
| title_sort | pharmacogenetics of oral antidiabetic drugs |
| url | http://dx.doi.org/10.1155/2013/686315 |
| work_keys_str_mv | AT matthijslbecker pharmacogeneticsoforalantidiabeticdrugs AT ewanrpearson pharmacogeneticsoforalantidiabeticdrugs AT ivantkac pharmacogeneticsoforalantidiabeticdrugs |